NASDAQ$ZIMV
ZimVie Inc · Q2 2025 earnings
Q2 2025 earnings · · After market close · Investor relations
Briefing
ZimVie reported Q2 2025 revenue of $116.7M, net income of $3.8M, diluted EPS of $0.15.
For Q2 2025, ZimVie reported Revenue was $116.7M, net income was $3.8M, diluted EPS was $0.15. Management discusses segment trends, liquidity, and outlook in the quarterly filing.
- Revenue $116.7M for Q2 2025.
- Net income $3.8M.
- Diluted EPS $0.15.
Headline financials
Revenue & EPS history
ZimVie · Revenue · Quarterly
$117M
Forward guidance
Healthcare outlook emphasizes reimbursement, pipeline milestones, and path to profitability.
Tailwinds
- Product launches and partnership economics.
- Cost discipline and cash runway.
Headwinds
- Clinical, regulatory, and pricing risk.
- Operating losses until scale is reached.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 6 quarterly earnings reports · overlaid with Q2 2025
-1.7%
Avg return
Earnings day
-3.4%
Avg return
5 days after
-5.3%
Avg return
30 days after
44%
8 / 18 earnings
Positive
+24.0%
Q1 2023
Best reaction
-49.0%
Q4 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2025 | — | — | — | |
| Q2 2025 | -0.4% | -0.1% | +0.1% | |
| Q1 2025 | -4.4% | -4.8% | +2.2% | |
| Q4 2024 | -1.7% | +3.1% | -11.9% | |
| Q3 2024 | +0.6% | +5.5% | +6.2% | |
| Q2 2024 | -18.2% | -19.0% | -17.9% | |
| Q1 2024 | +5.7% | +4.8% | +0.8% | |
| Q4 2023 | -14.4% | -13.4% | -16.9% | |
| Q3 2023 | +5.4% | — | — | |
| Q2 2023 | -6.0% | — | — | |
| Q1 2023 | +24.0% | — | — | |
| Q4 2022 | -49.0% | — | — | |
| Q3 2021 | +20.0% | — | — | |
| Q3 2022 | +20.0% | — | — | |
| Q2 2021 | -8.2% | — | — | |
| Q2 2022 | -8.2% | — | — | |
| Q1 2021 | -6.5% | — | — | |
| Q4 2021 | +5.1% | — | — | |
| Q4 2020 | +5.1% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro